Cadonilimab (Anti-PD-1 & CTLA-4)

Synonyms: AK104

Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.

Cadonilimab (Anti-PD-1 & CTLA-4)

Purity & Quality Control

Choose Selective PD-1/PD-L1 Inhibitors

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 5
PD-1/PD-L1 Inhibitor 3 12
BMS-1 12
BMS202 22
CA-170 (AUPM-170)
SR 0987 IL17,RORγt
Spartalizumab (anti-PD-1)
Camrelizumab (anti-PD-1)
AUNP-12
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.

Product Details

CAS No. 2394841-59-7
Source CHO
Storage
(From the date of receipt)
-80℃

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cadonilimab (Anti-PD-1 & CTLA-4) | Cadonilimab (Anti-PD-1 & CTLA-4) supplier | purchase Cadonilimab (Anti-PD-1 & CTLA-4) | Cadonilimab (Anti-PD-1 & CTLA-4) cost | Cadonilimab (Anti-PD-1 & CTLA-4) manufacturer | order Cadonilimab (Anti-PD-1 & CTLA-4) | Cadonilimab (Anti-PD-1 & CTLA-4) distributor